Healthcare / Medical DevicesKOSDAQ
$1375.00
-35.00 (-2.48%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-4.1B · quality 55.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
49/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$142.0B
P/E
21.8x
↑EV/EBITDA
26.3x
↑ROE
6.9%
↑Gross Margin
44.8%
↓Debt/Equity
0.05
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+4.7%
FCF CAGR
—
FCF margin
-19.7%
FCF / Net income
-1.43x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $47.23B · net income $6.51B · FCF $-9.33B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $47.23B | $47.23B | $34.62B | $34.97B | $41.17B |
| Net Income | $6.51B | $6.51B | $59.7M | $1.63B | $-18.54B |
| EBITDA | $5.18B | $5.18B | $1.89B | $3.78B | $-9.90B |
| EPS | 63.00 | 63.00 | 1.00 | 21.00 | -279.00 |
| Gross Margin | 44.8% | 44.8% | 46.6% | 52.2% | 46.3% |
| Operating Margin | 8.1% | 8.1% | -3.2% | 8.7% | 1.0% |
| Net Margin | 13.8% | 13.8% | 0.2% | 4.7% | -45.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.05 | 0.05 | 0.05 | 0.07 | 1.14 |
| Current Ratio | 2.55 | 2.55 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-9.33B | $-9.33B | $700.7M | $-4.12B | $-6.31B |
| Returns | |||||
| ROE | 6.9% | 6.9% | 0.1% | 2.7% | -32.1% |
| Valuation | |||||
| P/E | 21.83 | 21.83 | 1040.00 | 56.19 | — |
| EV/EBITDA | 26.26 | 26.26 | 20.93 | 22.05 | — |
| P/B | 1.51 | 1.51 | 0.71 | 1.52 | 1.36 |
| Growth & Yield | |||||
| Revenue Growth | 36.4% | 36.4% | -1.0% | -15.1% | — |
| EPS Growth | 6200.0% | 6200.0% | -95.2% | 107.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
24.6%
EPS terminal req.
$122.01
Spread vs growth
6175.4%
5Y implied EPS CAGR
18.6%
EPS terminal req.
$147.63
Spread vs growth
6181.4%
10Y implied EPS CAGR
14.2%
EPS terminal req.
$237.76
Spread vs growth
6185.8%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+42.9%
Start / end P/E
962.0x → 21.8x
EPS bridge
1.00 → 63.00
Residual
-6059.3%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.